Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25598478 | 0.87 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3837450 | 0.85 | SLC6A2 (0.62) | SLC6A2SLC6A4CCR5 | |
| Hydrochloric Acid SCHEMBL18263847 | 0.83 | SLC6A2 (0.60) | SLC6A2SLC6A4 | |
| SCHEMBL4385623 | 0.80 | CCR5 (0.66) | CYP3A4CCR5 | |
| SCHEMBL28759723 | 0.79 | CHRNB2 (0.41) | SLC6A2SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL31023740 | 0.79 | CYP3A4 (0.41) | CYP3A4SLC6A2SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL10112721 | 0.78 | TNF (0.40) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27544747 | 0.76 | SLC6A2 (0.40) | CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL12232428 | 0.76 | SLC6A2 (0.57) | SLC6A2SLC6A4 | |
| SCHEMBL16503429 | 0.76 | SLC6A2 (0.57) | SLC6A2SLC6A4CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379504-B1 | BIPIPERIDINYL-DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTORS INHIBITORS | NOVARTIS PHARMA GMBH (AT) | 2009-10-28 | — | — | EP | disclosed |
| CN-100469767-C | Bipiperidine derivatives and their use as chemokine receptor inhibitors | NOVARTIS AG (CH) | 2009-03-18 | — | — | CN | disclosed |
| US-20040142920-A1 | Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors | NOVARTIS | 2004-07-22 | — | — | US | disclosed |
| CN-1501915-A | Bipiperidine derivatives and their use as chemokine receptor inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| EP-1379504-A1 | BIPIPERIDINYL-DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTORS INHIBITORS | Novartis Pharma GmbH (AT) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002081449-A1 | BIPIPERIDINYL-DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTORS INHIBITORS | NOVARTIS AG (CH) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142920-A1 | Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors | CCR5, CCR2, CXCR3 | CYP3A4 1772/4885SLC6A2 3012/4885SLC6A4 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.